Anaconda BioMed reposted this
“The IDE approval marks an exciting milestone in our company’s mission to deliver new, safe and effective solutions that can meaningfully improve the treatment of stroke." Anaconda BioMed has announced that it has received conditional IDE approval from the FDA to begin the ATHENA study of its ANA Funnel Catheter. Read more: https://lnkd.in/eX8HkjfA #MedTech #Catheters #Regulation
We have very exciting news: ''We have received conditional IDE approval from the U.S. Food and Drug Administration to begin the ATHENA study of its ANA Funnel Catheter'' Press Release: https://lnkd.in/duYyKEjc Thank you very much 🐍
Remembering with a lot of emotional hangover the last team building we did last June, "CONDAYAK" 🌊. A very special moment was the celebration of our colleagues who have completed 5 years in Anaconda! 😍 As always we enjoyed two wonderful days together as a team 😜. We are lucky to be part of an organisation where people are at the centre of everything, and we work to create connections outside the workplace 💚. #CONDAYAK #teambulding #newexperiences
Our CEO, Francois Salmon, was at the MedTech Strategist in Dublin to demonstrate Anaconda Biomed's dedication to finding a safe and efficient way to perform a mechanical thrombectomy. A big thank you to everyone involved and to all those who support our project 🐍 Innogest Capital Ysios Capital Omega Funds Asabys Partners #MedTechStrategist #MedTechInnovation
Now presenting at #InnovationDublin24 is Anaconda BioMed with CEO Francois Salmon Remain informed on new articles, conference updates and more with our helpful medtech community newsletter. Subscribe here: https://bit.ly/42KHJKI The ANA5 system from Anaconda Biomed (Sant Quirze -Barcelona- Spain) is intended to be inserted and navigated to the neurovascular anatomy. The funnel is deployed by retracting the conduit catheter and is intended, when deployed, to provide temporary vascular flow restriction. The device is indicated for restoring blood flow in patients experiencing an acute ischemic stroke due to large vessel occlusion. Anaconda Biomed aims to increase penetration of mechanical thrombectomy for stroke by optimizing its device to achieve the benefits of “The First Pass Effect.
Yesterday was a very special day, it was Anaconda's 9th anniversary!!! 🐍 🎂 Thank you to all the people who make this project possible, you are a fundamental part of our work.🧡 Innogest Capital, Ysios Capital, Omega Funds, Asabys Partners Lunch: L'obrador catering Delicious!
🍾 MedTech Strategist is honored to welcome Anaconda BioMed alongside CEO Francois Salmon as a Presenting Company at the 10th Annual Innovation Summit Dublin 2024. 🧠 Presenting in the Stroke and Mechanical Thrombectomie Therapeutic Categories, The ANA5 system from Anaconda Biomed (Sant Quirze -Barcelona- Spain) is intended to be inserted and navigated to the neurovascular anatomy. The funnel is deployed by retracting the conduit catheter and is intended, when deployed, to provide temporary vascular flow restriction. The device is indicated for restoring blood flow in patients experiencing an acute ischemic stroke due to large vessel occlusion. 🥂 Welcome to #InnovationDublin24, Francois and Anaconda Biomed! 🤝 Celebrate 10 years of Innovation Summit in Dublin, Ireland April 16-18, 2024. Request to register now: https://bit.ly/48M8npY #medtech #medicaldevices #medtechindustry #medtechinnovation #stroke #strokeawareness #strokecare
Veterinary Surgeon and Study Director at IMMR
1moCongratulations for this new milestone !!! 🥳